|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Laboratorios Andromaco S.A.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Laboratorios Andromaco S.A. Headquarters Av. Quilin 5273 Penalolen; Santiago; Metropolitana |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Fiscal ID (RUT): 924480009 Fiscal ID (ISIN CODE ): CL0000000464 Financial Auditors: Ernst & Young (2011) Incorporation Date: August 30, 2000 Total Employees: 761 Tel: +56 2 594 8000 |
|
Company Description |
| Marketing and production of drugs of excellent quality and efficiency. The company represents important international pharmaceuticals firms, through which it incorporates exclusive and innovative products to its offer, for disease prevention and treatment. In addition, Andrómaco plays an active role contributing to generate pharmaceutical knowledge trough the research and development of vanguard products. The company is formed by Laboratorios Andrómaco S.A., Laboratorios Silesia S.A., ABL Pharma, | ||
|
||
Company Analysis |
| According to the Consolidated - Audited financial statement for the first two cumulated quarters of 2012, total net operating revenues increased with 5.58%, from CLP 40,581,696 thousands to CLP 42,846,398 thousands. Operating result decreased from CLP 3,110,041 thousands to CLP 1,939,085 thousands which means -37.65% change. The results of the period reached CLP -673,535 thousands at the end of the period against CLP 1,190,916 thousands last year. Return on equity (Net income/Total equity) went from 2.88% to -1.61%, the Return On Asset (Net income / Total Asset) went from 1.20% to -0.59% and the Net Profit Margin (Net Income/Net Sales) went from 2.93% to -1.57% when compared to the same period of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.51 to 1.74 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Q3C (cons) |
2012 Q2C (cons) |
|
 | ||
| Audited | Audited | |
| ||
| SVS - EEFF Sociedades Anonimas | SVS - EEFF Sociedades Anonimas | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
116,911,585 |
114,132,555 |
| ||
Current Assets |
76,882,627 |
73,494,191 |
| ||
Total Liabilities |
72,696,065 |
72,207,556 |
| ||
Shareholders Equity |
44,215,519 |
41,924,998 |
| ||
Current Liabilities |
43,993,584 |
42,155,488 |
| ||
| * All the accounts are in CLP. | ||
Income Statement
| ||
Operational Profit (Loss) |
7,133,929 |
1,939,085 |
| ||
Net Profit (Loss) |
2,354,994 |
-673,535 |
| ||
| * All the accounts are in CLP. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
2.01% |
-0.59% |
| ||
Return on Equity (ROE) |
5.33% |
-1.61% |
| Efficiency Ratios | ||
| ||
Current asset turnover |
0.90x |
0.58x |
| ||
Fixed-asset turnover |
1.73x |
1.05x |
| Liquidity Ratios | ||
| ||
Current Ratio |
174.76% |
174.34% |
| ||
Quick ratio |
131.1% |
122.6% |
| ||
Doom's day ratio |
2.31% |
2.21% |
| Leverage Ratios | ||
| ||
Leverage ratio |
160.82% |
158.06% |
| ||
Debt to equity |
164.41% |
172.23% |
| ||
Debt to total assets |
62.18% |
63.27% |
| ||
 |